Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0027651 (tumor)
 685,946 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Human melanoma cells secret a 21-kDa protein, termed CSC-21K, which binds with 1:1 molar stoichiometry to the matrix metalloproteinase type IV collagenase proenzyme (70-kDa gelatinase) secreted by the same cells. This binding protein has been purified and its complete primary structure determined by sequencing overlapping peptides which span the entire protein. The amino acid sequence demonstrates that this protein shares significant homology with human TIMP (tissue inhibitor of metalloproteinase), including conservation of the positions of the 12 cysteine residues and 3 of 4 tryptophan residues. The identification of CSC-21K now indicates that a family of TIMP-related proteins exists. Individual members of this family may possess selective affinities for different members of the matrix metalloproteinase family. CSC-21K produced by tumor cells is isolated as a 1:1 molar complex with type IV procollagenase, as demonstrated by amino acid composition analysis. Addition of purified CSC-21K to the activated metalloproteinase results in inhibition of the collagenolytic activity in a stoichiometric fashion. Based on its sequence homology to TIMP and ability to inhibit type IV collagenolysis we propose the name TIMP-2 for this inhibitor.
 ...
PMID:Tissue inhibitor of metalloproteinase (TIMP-2). A new member of the metalloproteinase inhibitor family. 279 61

A major problem in treatment of cancers arising in steroid-sensitive cells is their inevitable progression to a steroid-insensitive state; current therapies are based on the assumption that hormone insensitivity is associated with loss of receptor. We demonstrate for the first time that breast tumor cells can progress to steroid insensitivity in spite of functional steroid receptors. Transfection of the steroid-inducible LTR-C3 gene into unresponsive S115 mouse mammary tumor cells results in full inducibility of that gene with both androgen and glucocorticoid. Thus, although all known endogenous inducible parameters are lost, the steroid sensitivity of a transfected exogenous gene demonstrates that the machinery for steroid responsiveness is still fully functional. Furthermore, these transfected genes retain steroid sensitivity only while steroid is present; on prolonged withdrawal of steroid, they lose responsiveness, implying an epigenetic mechanism is involved.
 ...
PMID:Progression to steroid insensitivity can occur irrespective of the presence of functional steroid receptors. 282 60

Due to the peculiar type of replication and genome structure, retroviruses (RNA tumor viruses) are characterized by an intensive interaction with the genome of the infected cell. For replication, transcription of the viral RNA genome into double-stranded DNA and subsequent integration of the viral information into the cellular genome are requisite. The recombinatory events with the cellular DNA provide ample opportunities to generate new viral genome structures with altered information and to influence the expression of cellular genes. The lack of specificity of the integration process may lead to inactivation of cellular genes by insertion mutagenesis. The enhancer and promoter sequences of the proviral LTR (long terminal repeat) regions are able to activate the expression of cellular genes in the neighborhood of integration sites. Transforming retroviruses have acquired cellular genes as oncogenes the transcriptional products of which may trans-activate other genes of the host cell. Retroviral infection may result in malignant transformation and alteration of the differentiation pattern of the invaded cell. Depending on the cell type, a loss of expression of cellular functions (dedifferentiation) or an induction of differentiation processes is noticeable. The demonstration of cellular oncogenes (proto-oncogenes) and their activation by retroviruses has initiated new perspectives in understanding the regulation of cell growth and differentiation as well as the formation of tumors at the molecular level.
 ...
PMID:[Interaction of retroviruses and oncogenes with the cellular genome. 1]. 282 31

The structure of the integration site of plasmid with LTR of Rous sarcoma virus (pLTR1,5) in the genome of nude mice tumors, induced as a result of N1H3T3 cells' implantation, cotransfected by pLTR1,5 with the DNA of malignant human glioma cells, carrying amplified c-Ha-ras genome, has been studied. The restriction map of the investigated region of the cell genome was obtained. Molecular cloning of the integrated plasmid and adjacent cell sequences has been carried out. It was shown that the exogenic vector in the DNA of the tumor cells is included in BamHI structure of the repeat of mice genome.
 ...
PMID:[Transfection of a plasmid with a retrovirus promoter: distribution of sequences in the genome of induced tumors]. 283 68

Potential mechanisms of TNF-alpha action on tumor cells have been investigated in a model of mouse fibroblasts transformed by distinct retroviral vectors carrying the v-mos, c-myc, and v-Ha-ras oncogene, respectively. Treatment of v-mos and c-myc transformed cells with murine rTNF-alpha in non-cytotoxic concentrations caused a strong inhibition of both proliferative capacity in monolayer culture and colony formation in soft agar. In contrast, v-Ha-ras transformed cells showed little sensitivity to TNF-alpha treatment. These changes in cell growth characteristics of v-mos and c-myc transformants was preceded by a selective reduction of oncogene-specific steady RNA levels, whereas no RNA down-regulation was observed for v-Ha-ras transformants. An unchanged transcriptional activity of the LTR-controlled v-mos and c-myc genes, but a decreased half-life of oncogene-specific mRNA suggests that TNF-alpha primarily affects stability of v-mos and c-myc RNA without influencing the activity of retroviral promoters. This is confirmed by an unchanged chloramphenicol acetyl transferase activity in TNF-treated LTR-chloramphenicol acetyl transferase transformants. Removal of TNF-alpha from cultures of reverted cells provoked a rapid retransformation, with full recovery of neoplastic growth characteristics 10 days after abrogation of TNF-alpha treatment. These data suggest that in cases of non-cytocidal action of TNF-alpha persistent suppression of tumor cell growth requires continuous TNF-alpha treatment.
 ...
PMID:Tumor necrosis factor-alpha affects LTR-controlled oncogene expression in transformed mouse fibroblasts at the post-transcriptional level. 284 96

Effects of tumor, operative stress and tumor removal, and postoperative TPN of varying amino acid compositions on brain levels of tryptophan or tyrosine as predicted by their brain influx rates were studied in normals and in malnourished cancer patients. Concentrations of the large neutral amino acids (LNAA) were determined in patients before and after tumor removal, and in postoperative patients before and after receiving either a standard TPN solution (STD-TPN), or a branched-chain amino acid solution (BCAA-TPN). The LNAA were altered in all groups versus normals. Brain influx rates showed the following: in preoperative patients, predicted brain tryptophan levels were below normal (P less than 0.001), whereas tyrosine levels were within or above normal; no significant differences between pre- and postoperative tryptophan or tyrosine levels; postoperative STD-TPN did not change predicted brain tryptophan concentration from preinfusion values, but BCAA-TPN decreased it (P less than 0.001), underscoring the common transport carrier; and preinfusion predicted brain tyrosine levels were decreased (P less than 0.001) by both types of TPN solutions. These results imply low substrate levels for brain serotonin and catecholamine synthesis, possibly affecting functions dependent on their control.
 ...
PMID:Observations on predicted brain influx rates of neurotransmitter precursors. Effects of tumor, operative stress with tumor removal, and postoperative TPN of varying amino acid compositions. 288 Jun 57

Pancreatic ductal adenocarcinoma was induced in female Syrian golden hamsters by injecting N-nitrosobis(2-oxopropyl)amine (BOP) once a week at a dose of 10 mg per kg of body weight for 18 weeks. Hamsters were then treated with somatostatin analog D-Phe-Cys-Tyr-D-Trp-Lys-Val-Cys-Trp-NH2 (RC-160) or with [6-D-tryptophan]luteinizing hormone-releasing hormone [( D-Trp6]LH-RH) delayed delivery systems. Microcapsules of somatostatin analog RC-160, designed to release a dose of 5 micrograms/day, were injected twice a month and microcapsules of [D-Trp6]LH-RH, calculated to liberate 25 micrograms per day, once a month. After 18 weeks of BOP administration, the hamsters were divided into three groups of 10-20 animals each. Group I consisted of untreated controls, group II was injected with RC-160, and group III was injected with [D-Trp6]LH-RH. A striking decrease in tumor weight and volume was obtained in animals treated with [D-Trp6]LH-RH or with the somatostatin analog RC-160. After 45 days of treatment with either analog, the survival rate was significantly higher in groups II and III (70%), as compared with the control group (35%). The studies, done by light microscopy, high-resolution microscopy, and electron microscopy, showed a decrease in the total number of cancer cells and changes in the epithelium, connective tissue, and cellular organelles in groups II and III treated with the hypothalamic analogs as compared to controls. These results in female hamsters with induced ductal pancreatic tumors confirm and extend our findings, obtained in male animals with transplanted tumors, that [D-Trp6]LH-RH and somatostatin analogs inhibit the growth of pancreatic cancers.
 ...
PMID:Treatment of nitrosamine-induced pancreatic tumors in hamsters with analogs of somatostatin and luteinizing hormone-releasing hormone. 288 Dec 96

In experiments with whole animals infested with a highly malignant strain of Ehrlich ascites tumor cells, serial concentrations of amino acids were determined for host plasma, ascitic fluid, and tumor cells, throughout tumor development. Concentration gradients of glutamine, asparagine, valine, leucine, isoleucine, phenylalanine, tyrosine, histidine, tryptophan, arginine, serine, methionine, and taurine from the host plasma toward the ascitic liquid were established; while on the other hand, concentration gradients from the ascitic liquid toward the plasma were established for glutamate, aspartate, glycine, alanine, proline, and threonine. With the exception of aspartate the concentrations of these amino acids were highest inside the cells. Arginine was the only amino acid not detected in tumor cells. In vitro incubations of tumor cells in the presence of glutamine and/or glucose, as the energy and nitrogen sources, confirmed the amino acid fluxes previously deduced from the observed relative concentrations of amino acids in plasma, ascitic liquid, and tumor cells, suggesting that glutamate, alanine, aspartate, glycine, and serine can be produced by tumors. These findings support that changes in amino acid patterns occurring in the host system are related to tumor development.
 ...
PMID:Nitrogen metabolism in tumor bearing mice. 291 52

The combination of hormonal treatment based on a long-acting delivery system for the agonist [6-D-tryptophan]luteinizing hormone-releasing hormone ([D-Trp6]-LH-RH) with the chemotherapeutic agent Novantrone (mitoxantrone dihydrochloride) was studied in the Dunning R3327H rat prostate cancer model. Microcapsules of [D-Trp6]-LH-RH formulated from poly(DL-lactide-co-glycolide) and calculated to release a controlled dose of 25 micrograms/day were injected intramuscularly once a month. Novantrone (0.25 mg/kg) was injected intravenously once every 3 weeks. Three separate experiments were carried out. When the therapy was started 45 days after transplantation and continued for 70 days, tumor volume in the presence of the microcapsules (966 +/- 219 mm3) or Novantrone (3606 +/- 785 mm3) given alone was significantly decreased compared to controls (14,476 +/- 3045 mm3). However, the combination of microcapsules and Novantrone caused a greater inhibition of tumor growth (189 +/- 31 mm3) than the single agents. Similar effects were seen when the percent increase in tumor volume was examined. Tumor volume increased 10,527 +/- 1803% for the control group. The inhibition of growth caused by the [D-Trp6]LH-RH microcapsules alone (672 +/- 153% increase in volume) was again greater than that caused by Novantrone alone (2722 +/- 421% increase). The combination of the two agents was again the most effective, resulting in an increase in tumor volume of only 105 +/- 29%. Control tumors weighed 30.0 +/- 6.5 g. Tumor weights were much less in the groups treated with either microcapsules (3.28 +/- 0.69 g) or Novantrone (19.53 +/- 3.3 g) alone. The lowest tumor weights after 70 days of treatment were obtained in the group that received the combination of [D-Trp6]LH-RH microcapsules and Novantrone (1.02 +/- 0.2 g). Testes and ventral prostate weights were significantly diminished by the administration of microcapsules of [D-Trp6]LH-RH alone or in combination with Novantrone. In both of these groups, luteinizing hormone and prolactin levels were reduced and serum testosterone was suppressed to undetectable levels. Similar results were obtained in two other experiments in which the duration of treatment was 60 or 105 days. These results suggest that the overall response could reflect the inhibition of proliferation of hormone-independent cancer cells by Novantrone in addition to the suppressive effect of [D-Trp6]LH-RH on the growth of androgen-dependent tumor cells. The administration of Novantrone in combination with microcapsules of [D-Trp6]LH-RH might produce a better clinical response than LH-RH analog alone in patients with advanced prostate carcinoma.
 ...
PMID:Combination of a long-acting delivery system for luteinizing hormone-releasing hormone agonist with Novantrone chemotherapy: increased efficacy in the rat prostate cancer model. 294 45

The phototoxicity of hematoporphyrin derivative (Hpd) to murine bladder tumor (MBT-2) cells was studied in vitro. It was observed that selenium in the form of sodium selenite enhanced Hpd-sensitized photodamage in MBT-2 cells under conditions where selenite alone was non-toxic. Sodium selenite enhanced the fluorescence emission of Hpd and augmented the Hpd-sensitized photooxidation of tryptophan. The data suggest that sodium selenite is able to disaggregate Hpd, thereby enhancing Hpd-sensitized phototoxicity.
 ...
PMID:Selenium-induced enhancement of hematoporphyrin derivative phototoxicity in murine bladder tumor cells. 294 95


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>